CNS Treatment Developer Supernus Pharma (SUPN) Lowers IPO Expectations
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The Company lowered its expected offering, now expecting to sell 11 million common shares are a price of $5 per share.
Supernus previously expected to sling 5,769,000 shares at an expected price range of $12 to $14 per share.
The pharma plans to list on the Nasdaq Global Market under the ticker "SUPN."
The offering is being made through Citigroup, Piper Jaffray, Cowen and Company, and Stifel Nicolaus Weisel.
Supernus is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.
Supernus previously expected to sling 5,769,000 shares at an expected price range of $12 to $14 per share.
The pharma plans to list on the Nasdaq Global Market under the ticker "SUPN."
The offering is being made through Citigroup, Piper Jaffray, Cowen and Company, and Stifel Nicolaus Weisel.
Supernus is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Metals Acquisition prices $275M IPO on Nasdaq
- Exascale Labs and BCAR set shareholder vote for July 29 merger
- Citi Adds Four Names to Catalyst Call List
Create E-mail Alert Related Categories
IPOsRelated Entities
Piper Jaffray, Stifel, Citi, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
